Poly-L-Lactic Acid

被引:0
作者
Caroline M. Perry
机构
[1] Adis International Inc.,
来源
American Journal of Clinical Dermatology | 2004年 / 5卷
关键词
Mast Cell Number; Dermal Thickness; Lipodystrophy Syndrome; Mononuclear Macrophage; Injection Session;
D O I
暂无
中图分类号
学科分类号
摘要
Poly-L-lactic acid, a synthetic biodegradable polymer, is available as an injectable intradermal implant for use in the correction and restoration of the signs of facial lipoatrophy in patients with HIV infection.In a 96-week noncomparative study in HIV-infected patients with severe facial lipoatrophy, 41% of patients treated with intradermal poly-L-lactic acid injections had a total cutaneous thickness of >10mm at the nasogenian fold at week 24. Poly-L-lactic acid was injected into multiple sites of each cheek at baseline and at weeks 2, 4, and 6.Significant (p < 0.001) increases from baseline in total cutaneous thickness were reported at all evaluation timepoints up to 96 weeks after the start of treatment.In a randomized, nonblind study, significant (p < 0.001) increases from baseline in dermal thickness were observed at week 24 in HIV-infected patients with facial lipoatrophy who received immediate or deferred (by 12 weeks) treatment with poly-L-lactic acid, administered by injection into multiple intradermal sites every 2 weeks (three injection sessions in total)Improvements in depression and anxiety scores, patient visual analog scale assessments, and photographic assessments were also reported in patients treated with poly-L-lactic acid in the immediate versus deferred treatment trial.Poly-L-lactic acid was generally well tolerated. No serious adverse events were reported.
引用
收藏
页码:361 / 366
页数:5
相关论文
共 24 条
[1]  
Moyle G(2004)Managing HIV lipoatrophy Lancet 363 412-4
[2]  
Sutinen J(2004)A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection HIV Med 5 82-7
[3]  
Moyle GJ(2002)HIV-associated facial lipoatrophy Dermatol Surg 28 979-86
[4]  
Lysakova L(2003)An objective case definition of lipodystrophy in HIV-infected adults: a case-control study Lancet 361 726-35
[5]  
Brown S(2001)Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy AIDS 15 2441-4
[6]  
James J(2003)Polylactic acid implants. A new smile for lipoatrophic faces AIDS 17 2533-5
[7]  
Carruthers A(2003)Polylactic acid implants (New-Fill) ® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA AIDS 17 2471-7
[8]  
Carruthers J(1993)Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA) J Biomed Mater Res 27 1135-48
[9]  
Carr A(1973)Resorption rate, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat J Biomed Mater Res 7 155-66
[10]  
Emery S(undefined)undefined undefined undefined undefined-undefined